• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?端粒酶逆转录酶（TERT）启动子突变：将世界卫生组织（WHO）二级星形细胞瘤诊断为异柠檬酸脱氢酶（IDH）野生型胶质母细胞瘤是否足够？
Neuro Oncol. 2021 Jun 1;23(6):865-866. doi: 10.1093/neuonc/noab052.
2
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.成人脑胶质瘤的靶向下一代测序用于回顾性预后评估和前瞻性诊断。
Neuropathol Appl Neurobiol. 2021 Feb;47(1):108-126. doi: 10.1111/nan.12645. Epub 2020 Aug 17.
3
Clinical implications of molecular analysis in diffuse glioma stratification.分子分析在弥漫性胶质瘤分层中的临床意义。
Brain Tumor Pathol. 2021 Jul;38(3):210-217. doi: 10.1007/s10014-021-00409-y. Epub 2021 Jul 15.
4
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.TERT 启动子突变及其与胶质瘤中 IDH 突变的相互作用：TERT 启动子和 IDH 突变的联合将低级别胶质瘤分为不同的生存亚组——基于汇总数据的荟萃分析。
Crit Rev Oncol Hematol. 2017 Dec;120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. Epub 2017 Oct 3.
5
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.弥漫性星形细胞瘤，IDH1/2 野生型，具有胶质母细胞瘤的分子特征，WHO 分级 IV：对 cIMPACT-NOW 标准的确认。
Neuro Oncol. 2020 Apr 15;22(4):515-523. doi: 10.1093/neuonc/noz200.
6
Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.对 IDH 野生型 WHO 分级 II-III 级胶质瘤进行临床、组织病理学和分子分析，以确定预后不良的遗传预测因子。
Brain Tumor Pathol. 2019 Oct;36(4):135-143. doi: 10.1007/s10014-019-00348-9. Epub 2019 Jul 19.
7
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.上皮样胶质母细胞瘤和伴发的低级别星形细胞瘤中TERT启动子与BRAF V600E的同时突变
Neuropathology. 2017 Feb;37(1):58-63. doi: 10.1111/neup.12318. Epub 2016 Jun 15.
8
When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.当终点成为起点：端粒酶靶向治疗胶质母细胞瘤。
Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):15. doi: 10.1007/s11910-018-0825-7.
9
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.通过对 2016 年 WHO 弥漫性胶质瘤分类进行以下四项指标的细化：EGFR 扩增、TERT 突变、PTEN 缺失和 MGMT 甲基化，获得的临床见解。
BMC Cancer. 2019 Oct 17;19(1):968. doi: 10.1186/s12885-019-6177-0.
10
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.端粒的非经典延长是 IDH1 突变星形细胞瘤中端粒维持的主要机制。
J Neurooncol. 2020 Mar;147(1):1-14. doi: 10.1007/s11060-020-03394-y. Epub 2020 Jan 20.

引用本文的文献

1
Unraveling the heterogeneity of WHO grade 4 gliomas: insights from clinical, imaging, and molecular characterization.解析世界卫生组织4级胶质瘤的异质性：来自临床、影像学和分子特征的见解
Discov Oncol. 2025 Feb 3;16(1):111. doi: 10.1007/s12672-025-01811-0.
2
Diagnostic impact of DNA methylation classification in adult and pediatric CNS tumors.DNA甲基化分类对成人和儿童中枢神经系统肿瘤的诊断影响
Sci Rep. 2025 Jan 22;15(1):2857. doi: 10.1038/s41598-025-87079-4.
3
Prognostic Impact of Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria.基于WHO2021标准的成人型弥漫性胶质瘤启动子突变的预后影响
Cancers (Basel). 2024 May 27;16(11):2032. doi: 10.3390/cancers16112032.
4
Unveiling divergent treatment prognoses in IDHwt-GBM subtypes through multiomics clustering: a swift dual MRI-mRNA model for precise subtype prediction.通过多组学聚类揭示 IDHwt-GBM 亚型中的不同治疗预后：一种快速的双重 MRI-mRNA 模型，用于精准的亚型预测。
J Transl Med. 2024 Jun 18;22(1):578. doi: 10.1186/s12967-024-05401-6.
5
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?端粒酶逆转录酶基因在胶质母细胞瘤中的生物学和临床作用：一种潜在的治疗靶点？
Cells. 2023 Dec 25;13(1):44. doi: 10.3390/cells13010044.
6
Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.新诊断的无对比增强（低级别外观）脑胶母细胞瘤的手术治疗和结果： RANO 切除组报告。
Neuro Oncol. 2024 Jan 5;26(1):166-177. doi: 10.1093/neuonc/noad160.
7
Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.青少年和青年中枢神经系统肿瘤的分子检测：加拿大指南。
Front Oncol. 2022 Sep 23;12:960509. doi: 10.3389/fonc.2022.960509. eCollection 2022.
8
Impact of new molecular criteria on diagnosis and survival of adult glioma patients.新分子标准对成人胶质瘤患者诊断和生存的影响。
IBRO Neurosci Rep. 2022 Sep 19;13:299-305. doi: 10.1016/j.ibneur.2022.09.005. eCollection 2022 Dec.
9
GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.GlioMarker：一个用于胶质瘤诊断生物标志物知识探索的综合数据库。
Front Oncol. 2022 Aug 11;12:792055. doi: 10.3389/fonc.2022.792055. eCollection 2022.
10
Chromosomal instability in adult-type diffuse gliomas.成人型弥漫性神经胶质瘤中的染色体不稳定性。
Acta Neuropathol Commun. 2022 Aug 17;10(1):115. doi: 10.1186/s40478-022-01420-w.

本文引用的文献

1
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.异柠檬酸脱氢酶野生型低级别弥漫性胶质瘤：组织学分级和分子评估对预后分层的重要性
Neuro Oncol. 2021 Jun 1;23(6):955-966. doi: 10.1093/neuonc/noaa258.
2
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.cIMPACT-NOW更新6：关于未来中枢神经系统肿瘤分类和分级的cIMPACT-乌得勒支会议的新实体和诊断原则建议。
Brain Pathol. 2020 Jul;30(4):844-856. doi: 10.1111/bpa.12832. Epub 2020 Apr 19.
3
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.cIMPACT-NOW更新5：IDH突变型星形细胞瘤的推荐分级标准和术语
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
4
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.弥漫性星形细胞瘤，IDH1/2 野生型，具有胶质母细胞瘤的分子特征，WHO 分级 IV：对 cIMPACT-NOW 标准的确认。
Neuro Oncol. 2020 Apr 15;22(4):515-523. doi: 10.1093/neuonc/noz200.
5
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".cIMPACT-NOW更新3：“弥漫性星形细胞胶质瘤，IDH野生型，具有胶质母细胞瘤分子特征，WHO四级”的推荐诊断标准。
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
6
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.脑肿瘤中 EGFR 扩增、染色体 7 联合增益和染色体 10 缺失以及 TERT 启动子突变的分布及其对 IDHwt 星形细胞瘤重新分类为胶质母细胞瘤的潜在影响。
Acta Neuropathol. 2018 Nov;136(5):793-803. doi: 10.1007/s00401-018-1905-0. Epub 2018 Sep 5.
7
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.弥漫性低级别胶质瘤的综合、整合基因组分析
N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?

作者信息

Giannini Caterina, Giangaspero Felice

机构信息

Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

出版信息

Neuro Oncol. 2021 Jun 1;23(6):865-866. doi: 10.1093/neuonc/noab052.

DOI:10.1093/neuonc/noab052
PMID:33660766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8168806/
Abstract
摘要